EP1848410A4 - Compositions d'administration particulaires, polymeriques, et leurs methodes d'utilisation - Google Patents

Compositions d'administration particulaires, polymeriques, et leurs methodes d'utilisation

Info

Publication number
EP1848410A4
EP1848410A4 EP06734169A EP06734169A EP1848410A4 EP 1848410 A4 EP1848410 A4 EP 1848410A4 EP 06734169 A EP06734169 A EP 06734169A EP 06734169 A EP06734169 A EP 06734169A EP 1848410 A4 EP1848410 A4 EP 1848410A4
Authority
EP
European Patent Office
Prior art keywords
methods
administration compositions
particulate polymeric
polymeric administration
particulate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP06734169A
Other languages
German (de)
English (en)
Other versions
EP1848410A1 (fr
Inventor
William G Turnell
Hong Li
Zaza D Gomurashvili
Jonathan Macferran Hughes
Jie Da
Huashi Zhang
Ramaz Katsarava
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medivas LLC
Original Assignee
Medivas LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medivas LLC filed Critical Medivas LLC
Publication of EP1848410A1 publication Critical patent/EP1848410A1/fr
Publication of EP1848410A4 publication Critical patent/EP1848410A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/593—Polyesters, e.g. PLGA or polylactide-co-glycolide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/595—Polyamides, e.g. nylon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2821—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against ICAM molecules, e.g. CD50, CD54, CD102
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L77/00—Compositions of polyamides obtained by reactions forming a carboxylic amide link in the main chain; Compositions of derivatives of such polymers
    • C08L77/12—Polyester-amides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Polymers & Plastics (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP06734169A 2005-02-17 2006-01-31 Compositions d'administration particulaires, polymeriques, et leurs methodes d'utilisation Withdrawn EP1848410A4 (fr)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US65471505P 2005-02-17 2005-02-17
US68467005P 2005-05-25 2005-05-25
US68757005P 2005-06-03 2005-06-03
US71995005P 2005-09-22 2005-09-22
US73740105P 2005-11-14 2005-11-14
US75917906P 2006-01-13 2006-01-13
PCT/US2006/003575 WO2006088647A1 (fr) 2005-02-17 2006-01-31 Compositions d'administration particulaires, polymeriques, et leurs methodes d'utilisation

Publications (2)

Publication Number Publication Date
EP1848410A1 EP1848410A1 (fr) 2007-10-31
EP1848410A4 true EP1848410A4 (fr) 2011-11-09

Family

ID=36916776

Family Applications (1)

Application Number Title Priority Date Filing Date
EP06734169A Withdrawn EP1848410A4 (fr) 2005-02-17 2006-01-31 Compositions d'administration particulaires, polymeriques, et leurs methodes d'utilisation

Country Status (6)

Country Link
EP (1) EP1848410A4 (fr)
JP (1) JP2008530206A (fr)
CN (1) CN101115471B (fr)
AU (1) AU2006214655A1 (fr)
CA (1) CA2596011C (fr)
WO (1) WO2006088647A1 (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060177416A1 (en) 2003-10-14 2006-08-10 Medivas, Llc Polymer particle delivery compositions and methods of use
CA2623198C (fr) * 2005-09-22 2014-08-05 Medivas, Llc Formules de poly(ester amide) et de poly(ester urethane) contenant des diesters de bis-(a-amino)-diol et methodes d'emploi
WO2007038246A2 (fr) 2005-09-22 2007-04-05 Medivas, Llc Compositions polymeres solides pour administration et methodes d'utilisation de celles-ci
EP2004145A4 (fr) * 2006-03-24 2013-07-03 Medivas Llc Poly(ester amides) biodegradables contenant du dicarboxylate d'alkylene et leurs methodes d'utilisation
US8658210B2 (en) 2006-04-17 2014-02-25 Advanced Cardiovascular Systems, Inc. Polyesteramide platform for site specific drug delivery
EP2021141A4 (fr) * 2006-05-09 2013-07-03 Medivas Llc Polymères hydrosolubles biodégradables
EP2068937A2 (fr) * 2006-09-05 2009-06-17 Medivas, LLC Compositions liposomales stabilisées par des polymères et leurs méthodes d'utilisation
EP2185626A4 (fr) * 2007-08-23 2010-09-08 Medivas Llc Compositions de transfert de gène de polymère biodégradable contenant des acides alpha-aminés cationiques
US9732142B2 (en) 2008-05-15 2017-08-15 Biocompatibles Uk Limited Intracellular antibody delivery
JP2012505957A (ja) * 2008-10-15 2012-03-08 メディバス エルエルシー プロリンベースの生分解性ポリマー
US9873765B2 (en) 2011-06-23 2018-01-23 Dsm Ip Assets, B.V. Biodegradable polyesteramide copolymers for drug delivery
ES2558357T3 (es) 2011-06-23 2016-02-03 Dsm Ip Assets B.V. Micro- o nanopartículas que comprenden un copolímero de poliesteramida biodegradable para uso en el suministro de agentes bioactivos
CA2969171C (fr) 2014-12-18 2023-12-12 Dsm Ip Assets B.V. Systeme d'administration de medicament pour administration de medicaments sensibles aux acides
WO2016207725A1 (fr) * 2015-06-23 2016-12-29 Phagelux (Canada), Inc. Composition comprenant des polymères d'acide aminé et un agent bioactif et procédé de préparation associé
US11090273B2 (en) * 2016-09-20 2021-08-17 Cornell University Tagged poly(ester amide urethane)s, nanoparticles formed from same, and uses thereof
CA3133177A1 (fr) * 2019-03-14 2020-09-17 Engene, Inc. Expression localisee, a base de polyplexeur de chitosane, d'il-12 seul ou en association avec des inducteurs ifn de type i pour le traitement de cancers muqueux
EP4058504A1 (fr) 2019-11-12 2022-09-21 DSM IP Assets B.V. Copolymères de polyesteramides possédant une température de transition vitreuse élevée
CN112321822B (zh) * 2020-12-02 2021-12-10 中山大学 一种具有ros响应性的蛋氨酸-聚酯酰胺高分子聚合物及其应用
CN114920869B (zh) * 2022-05-24 2023-07-14 太原工业学院 两亲性精氨酸嵌段环丙沙星共聚物、纳米颗粒及其制备方法和应用
CN119039583B (zh) * 2024-11-01 2025-03-11 浙江农林大学 一种具有立构复合结晶性能侧链碱基生物可降解聚酯酰胺及其酶促制备方法

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5449513A (en) * 1992-08-14 1995-09-12 Research Development Corporation Of Japan Physical trapping type polymeric micelle drug preparation
US5861387A (en) * 1991-06-28 1999-01-19 Endorecherche Inc. Controlled release systems and low dose androgens
US5874064A (en) * 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US20020015720A1 (en) * 2000-01-11 2002-02-07 Ramaz Katsarava Polymer blends as biodegradable matrices for preparing biocomposites
WO2003062298A1 (fr) * 2002-01-17 2003-07-31 Polyrava Llc Co-poly(ester amide) et co-poly(ester urethane) compositions presentant une biodegradabilite, procedes de production et utilisation associes
WO2004039944A2 (fr) * 2002-05-15 2004-05-13 Rutgers, The State University Polymeres triblocs pour administration de gene ou de medicament a base de nanospheres
EP1945682A2 (fr) * 2005-10-21 2008-07-23 Medivas, LLC Polymeres de poly(ester-uree) et leurs procedes d'utilisation

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020164374A1 (en) * 1997-10-29 2002-11-07 John Jackson Polymeric systems for drug delivery and uses thereof
CN1281355A (zh) * 1997-12-12 2001-01-24 三阳株式会社 用于基因递送的生物可降解性混合聚合胶束
DE10008880A1 (de) * 1999-02-19 2000-08-24 Bioserv Ag Bioabbaubare Komposite zur Herstellung von Mikrokapseln
CN1230206C (zh) * 2000-01-11 2005-12-07 内立蒂克斯股份有限公司 作为生产生物复合材料的生物可降解基质的聚合物混合物
JP2003519651A (ja) * 2000-01-14 2003-06-24 ブラウン ユニバーシティ リサーチ ファウンデーション 微紛化凍結乾燥粒子
FR2811227A1 (fr) * 2000-07-07 2002-01-11 Philippe Maincent Vecteurs particulaires destines a ameliorer l'absorption orale de principes actifs
US6503538B1 (en) * 2000-08-30 2003-01-07 Cornell Research Foundation, Inc. Elastomeric functional biodegradable copolyester amides and copolyester urethanes
CN1119172C (zh) * 2000-12-12 2003-08-27 天津大学 脂肪族聚酯表面的壳聚糖／明胶网络修饰方法
JP4679822B2 (ja) * 2002-03-13 2011-05-11 ノバルティス アーゲー 医薬微粒子
WO2003092585A2 (fr) * 2002-05-02 2003-11-13 Pr Pharmaceuticals, Inc. Compositions a liberation regulee de metabolites d'estradiol
CN101044638B (zh) * 2004-10-18 2012-05-09 株式会社明电舍 帕尔帖元件或塞贝克元件的结构及其制造方法

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5861387A (en) * 1991-06-28 1999-01-19 Endorecherche Inc. Controlled release systems and low dose androgens
US5449513A (en) * 1992-08-14 1995-09-12 Research Development Corporation Of Japan Physical trapping type polymeric micelle drug preparation
US5874064A (en) * 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US20020015720A1 (en) * 2000-01-11 2002-02-07 Ramaz Katsarava Polymer blends as biodegradable matrices for preparing biocomposites
WO2003062298A1 (fr) * 2002-01-17 2003-07-31 Polyrava Llc Co-poly(ester amide) et co-poly(ester urethane) compositions presentant une biodegradabilite, procedes de production et utilisation associes
WO2004039944A2 (fr) * 2002-05-15 2004-05-13 Rutgers, The State University Polymeres triblocs pour administration de gene ou de medicament a base de nanospheres
EP1945682A2 (fr) * 2005-10-21 2008-07-23 Medivas, LLC Polymeres de poly(ester-uree) et leurs procedes d'utilisation

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ARABULI N ET AL: "HETEROCHAIN POLYMERS BASED ON NATURAL AMINO ACIDS. SYNTHESIS AND ENZYMATIC HYDROLYSIS OF REGULAR POL(ESTER AMIDE)S BASED ON BIS(L-PHENYLALANINE)ALPHA,OMEGA-ALKYLENE DIESTERS AND ADIPIC ACID", MACROMOLECULAR CHEMISTRY AND PHYSICS, WILEY-VCH VERLAG, WEINHEIM, DE, vol. 195, no. 6, 1 January 1994 (1994-01-01), pages 2279 - 2289, XP002171341, ISSN: 1022-1352, DOI: 10.1002/MACP.1994.021950633 *
See also references of WO2006088647A1 *

Also Published As

Publication number Publication date
CA2596011A1 (fr) 2006-08-24
CA2596011C (fr) 2013-05-14
JP2008530206A (ja) 2008-08-07
CN101115471A (zh) 2008-01-30
WO2006088647A1 (fr) 2006-08-24
AU2006214655A1 (en) 2006-08-24
EP1848410A1 (fr) 2007-10-31
CN101115471B (zh) 2011-02-09

Similar Documents

Publication Publication Date Title
FR20C1019I2 (fr) Promedicaments de composes de 2,4-pyrimidinediamine et leurs utilisations
EP1765379A4 (fr) Compositions pharmaceutiques de co-cristal et methodes d'utilisation associees
EP2104513A4 (fr) Compositions d'anticorps ovr110 et leurs procédés d'utilisation
EP1551376A4 (fr) Compositions immunomodulatrices, leurs methodes de preparation et utilisation
EP1906965A4 (fr) Composes d'azaindazole et methodes d'utilisation desdits composes
EP1762234A4 (fr) Activateur d'ampk
FR2888850B1 (fr) Nouveaux anticorps anti-igf-ir et leurs applications
EP1706791A4 (fr) Compositions de photoresines et leurs procedes d'utilisation
EP1701725A4 (fr) Methodes et compositions
EP2178549A4 (fr) Peptide antimicrobien, compositions et procédés d'utilisation
EP1513825A4 (fr) Medicament anti-tuberculeux: compositions et methodes
EP1626717A4 (fr) Benzimidazoles, compositions contenant lesdits composes et methodes d'utilisation
EP1799232A4 (fr) Systemes d'alginate auto-gelifiants et utilisations associees
EP2076246A4 (fr) Formation de gels médicalement utiles comprenant des particules microporeuses et leurs procédés d'utilisation
EP1933884A4 (fr) Agents d'imagerie et leurs procédés d'utilisation
EP2066294A4 (fr) Compositions immunomodulatrices et leurs procédés d'utilisation
FR2912310B1 (fr) Nouvelles compositions cosmetiques et/ou pharmaceutiques et leurs applications.
EP2101825A4 (fr) Agents d'administration de 2-nitroimidazole faiblement basique, sélective de l'hypoxie, et procédés d'utilisation de ceux-ci
ATE419839T1 (de) Trockengranulierungzusammensetzung enthaltend emtricitabine und tenofovir df
EP2061800A4 (fr) Compositions comprenant hmw-maa et des fragments de celui-ci, et leurs procédés d'utilisation
EP1756041A4 (fr) Composes polycationiques et leurs utilisations
MA29030B1 (fr) 2-alcoxy-3,4,5-trihydroxy-alkylamides, leur preparation, compositions les contenant et utilisation
EP1708719A4 (fr) Compositions pharmaceutiques aqueuses de 2,6-diisopropylphenol (propofol) et leurs utilisations
EP1979269A4 (fr) Formulations de chlorite et leurs procédés de préparation et d'utilisation
EP1954685A4 (fr) Composes furoxane, compositions et procedes d'utilisation

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20070817

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20111011

RIC1 Information provided on ipc code assigned before grant

Ipc: C08L 75/02 20060101ALI20111005BHEP

Ipc: C08L 75/04 20060101ALI20111005BHEP

Ipc: A61K 9/16 20060101ALI20111005BHEP

Ipc: A61K 47/48 20060101ALI20111005BHEP

Ipc: A61K 9/51 20060101ALI20111005BHEP

Ipc: C08L 75/06 20060101ALI20111005BHEP

Ipc: A61L 31/00 20060101ALI20111005BHEP

Ipc: A61F 2/00 20060101ALI20111005BHEP

Ipc: C12N 15/88 20060101ALI20111005BHEP

Ipc: C08L 77/12 20060101ALI20111005BHEP

Ipc: C07K 16/28 20060101ALI20111005BHEP

Ipc: A61K 9/107 20060101ALI20111005BHEP

Ipc: A61K 47/34 20060101ALI20111005BHEP

Ipc: A61K 9/50 20060101ALI20111005BHEP

Ipc: C08L 77/00 20060101AFI20111005BHEP

Ipc: C08G 18/10 20060101ALI20111005BHEP

Ipc: C08G 69/44 20060101ALI20111005BHEP

17Q First examination report despatched

Effective date: 20121022

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

RIC1 Information provided on ipc code assigned before grant

Ipc: C08L 75/04 20060101ALI20170202BHEP

Ipc: C08G 69/44 20060101ALI20170202BHEP

Ipc: A61K 9/51 20060101ALI20170202BHEP

Ipc: A61K 9/16 20060101ALI20170202BHEP

Ipc: C07K 16/28 20060101ALI20170202BHEP

Ipc: A61K 9/50 20060101ALI20170202BHEP

Ipc: C12N 15/88 20060101ALI20170202BHEP

Ipc: C08G 18/10 20060101ALI20170202BHEP

Ipc: A61F 2/00 20060101ALI20170202BHEP

Ipc: C08L 77/00 20060101AFI20170202BHEP

Ipc: C08L 75/02 20060101ALI20170202BHEP

Ipc: C08L 77/12 20060101ALI20170202BHEP

Ipc: A61L 31/00 20060101ALI20170202BHEP

Ipc: A61K 9/107 20060101ALI20170202BHEP

Ipc: A61K 47/34 20170101ALI20170202BHEP

Ipc: C08L 75/06 20060101ALI20170202BHEP

INTG Intention to grant announced

Effective date: 20170220

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20170704